Intensity-modulated radiotherapy (IMRT) has reduced the impact of acute and late toxicities associated with head and neck radiotherapy. Treatment planning system (TPS) advances in biological cost function based optimization (BBO) and improved segmentation techniques have increased organ at risk (OAR) sparing compared to conventional dose-based optimization (DBO). A planning study was undertaken to compare OAR avoidance in DBO and BBO treatment planning. Simultaneous integrated boost treatment plans were produced for 10 head and neck patients using both planning systems. Plans were compared for tar get coverage and OAR avoidance. Comparisons were made using the BBO TPS Monte Carlo dose engine to eliminate differences due to inherent algorithms.
Introduction
Radiotherapy is a proven modality in providing local regional control and improving survival outcomes in head and neck cancer patients (1, 2). Intensity modulated radiation therapy (IMRT) reduces treatment related toxicities through the creation of steep dose gradients at the target and organ at risk (OAR) interface, as well as modulating dose to avoid OARs that are located within the concavities of irregularly shaped targets (3-5). Delivering highly conformal doses to target volumes, while maintaining and improving critical structure avoidance, is significantly improved with IMRT planning and treatment delivery (6-9). Yet head and neck IMRT continues to present planning challenges with numerous dose limiting structures neighboring tumors within this anatomical site. This has lead to multiple evaluations assessing OAR avoidance with IMRT (10, 11) . Recent developments in radiotherapy treatment planning systems (TPS) have seen the introduction of biological cost function based optimization (BBO). This approach enables inverse planned IMRT using prescriptions based on biological cost functions as well as, or instead of conventional DVH constraints. Biological cost functions are based on equivalent uniform doses (EUD's) rather than physical dose constraints such as maximum and minimum dose, or points on a dosevolume histogram (DVH). They include cost functions based on serial and parallel complication models, where the optimizer minimizes the EUD to the OAR in its entirety. BBO has also been combined with a number of other improved planning techniques compared to traditional dose-based optimization (DBO), including constrained fluence optimization and constrained aperture optimization. An efficient Monte Carlo (MC) dose calculation is used by the BBO TPS, enabling increased dose accuracy (compared to DBO's superposition (SP) algorithms) within a clinically acceptable calculation time (12). Combining these features, the anticipated OAR dose reduction may lead to improved planned dosimetry and improved quality of life for this patient group (13, 14) . Numerous planning studies have provided a comparison of commercial treatment planning systems (15, 16). Semenenko et al. provided a dosimetric comparison of commercially available BBO and DBO TPS utilizing each systems' inherent calculation algorithm (15). Our study aimed to extend the findings of Semenenko, to not only derive the potential benefits of BBO in the head and neck, but the potential dosimetric impact on multiple structures when different algorithms are utilized. A planning study was undertaken to compare the optimization techniques of one commercially available DBO TPS and one BBO TPS. Further to this, each DBO plan was recalculated using a like Monte Carlo calculation algorithm, to gain a true dose discrepancy and any subsequent dosimetric impact through removing any bias associated with different calculation engines.
Methods and Materials
In this institutional ethics approved study, treatment plans were produced for ten consecutive patients with histologically confirmed squamous cell carcinoma (SCC) of the head and neck deemed clinically suitable for curative radiotherapy with IMRT. Two patients presented with 'Mx' disease, and were treated radically accordingly. Treatment plans clinically accepted and delivered with DBO using the XiO v4.33.02 TPS (Elekta CMS Software, St Louis, MO, USA) were generated on BBO using the Monaco v1.0.2 TPS (Elekta CMS Software, St Louis, MO, USA) for plan comparison with the previously accepted DBO plans.
Patient demographics, tumor and treatment characteristics are shown in Table I . The prescribed doses were planned via a simultaneous integrated boost (SIB), to a gross tumor volume (GTV) or tumor bed for post-operative radiation therapy (all referred to as GTV in this article), high risk clinical target volume (CTV) and low risk CTV. Dose to GTV (60-70 Gy), high risk CTV (60-63 Gy) and low risk CTV (54-56 Gy) was planned at 5 fractions per week over 6 to 7 weeks. Dose prescription was dependent on clinical intent (i.e. definitive/ post-operative). This study aimed to incorporate the spectrum of head and neck cases seen in a normal radiotherapy department, hence, the variety in dose prescription. It is hoped this would provide generalizable results to a normal head and neck cancer treatment population. Each target was expanded with a 1 cm GTV-CTV margin, and a further 0.5 cm margin to form PTV 1 , PTV 2 and PTV 3 respectively.
Optimized IMRT plans, deliverable via 7 equally spaced step-and-shoot segmented beams on a 6MV linear accelerator (Elekta Synergy, Elekta Oncology, Crawley, UK), were generated using both planning systems on 0.25 cm computed tomography slices. DBO plans were calculated using a Multigrid Superposition algorithm (17). Dose is computed by convolving the total energy released through Monte Carlogenerated energy deposition kernels (18). 0.2 cm grid spacing was used in the DBO plans. BBO plans were calculated using a MC calculation algorithm (XVMC/VEF-2% variance and 0.3 cm) as described and validated by Fippel et al. (12, 19, 20) . Benchmarking of this MC algorithm against the BEAM Monte Carlo code has also occurred (21). This was previously noted by Semenenko et al. (15) . Software limitations in the Monaco v1.0 didn't allow for calculation with 0.2 cm grid spacing.
A set of institutional dose goals (Table II) A matched pairs t-test between means was performed to determine the statistical significance of any discrepancies for the comparisons between the study groups.
Results
When comparing the results calculated with inherent calculation algorithms (i.e. DBO SP vs. BBO MC), the BBO TPS produces similar coverage for GTV and all PTVs. The CI also improves for PTV 1 and PTV 2 indicating a smaller and therefore more conformal BBO V95 (refer to Tables III and IV) . Major dose reductions were seen in larynx, parotids, spinal cord and brain stem (refer to Tables V and VI).
When the DBO plans were recalculated using BBO TPS's MC algorithm, the differences shown are closer to 'true' differences, calculated using the same, more accurate algorithm, eliminating discrepancy caused by the SP and MC dose calculation algorithms.
Target coverage (Tables III and IV) 
Discussion
The benefits of IMRT planning for head and neck cancers have been demonstrated based on both planning and clinical outcome studies including an early report from a randomized study (23). Improved OAR sparing with reduced radiation related side-effects have been documented. This retrospective planning study has examined the benefits of utilizing a new planning system based on biological cost functions with improved optimization and segmentation techniques, for inverse IMRT planning of complex head and neck cases. While similar planning studies have reported the benefits of the BBO TPS (15), our dose comparison utilizing the same Monte Carlo calculation engine provides grounds for a truer comparison, through the removal of factors inherent to each system. It also quantifies algorithm discrepancy, highlighting the potential dosimetric ramifications when alternate algorithms are utilized. This aspect has not been assessed in previous publications.
Equivalent uniform dose (or EUD) provides the theoretical basis for planning in the assessed BBO TPS. Niemierko initially introduced the concept of EUD as the biological equivalent dose that if given uniformly, will lead to the same cell kill in the tumor as the actual non-uniform dose distribution (24). Applied clinically, this theory dictates that the presence of a cold spot within a target would have a significant impact on the likelihood of tumor control. This is an aspect not necessarily quantified in traditional dose-volume based objectives. The basis for this understanding of EUD was later applied to normal tissue.
EUD-based objective functions, as described by Wu et al., rely heavily on three generally accepted concepts, in which (a) tumor control is a function of dose minimum to the tumor, (b) the biological response of serial functioning normal tissue is a function of dose maximum, and (c) parallel normal tissue have a biologic response more closely associated with mean dose (25). The BBO TPS utilizes a set of EUD-based objective functions based on these principles. The Poisson Cell Kill Cost Function works to eradicate cold spots within the target to enhance tumor control. The Serial and Parallel Cost Functions work on the dose maximum and mean respectively to ascertain the appropriate biological response. The results of this study draw parallels to that of Wu. The BBO TPS takes a similar approach to that of Wu. EUD optimization continues beyond planner-specified constraints, even once they have been met. In essence, while not understanding the 'true' optimal treatment plan, the EUD-based optimization provides a platform in which to converge on a better planning solution. EUD-based objectives work on the entire DVH curve, and not just the specific assigned dose request, allowing improved avoidance beyond the userdefined dose-volume levels. Utilizing the parallel-based cost function for the larynx prioritizes reduction of mid range DVH. However, the parallel-based cost function still works to reduce dose contribution at both the high and low ends of the DVH curve, whereas DBO utilizes user-defined point/s on the DVH.
EUD-based cost functions appear to minimize dose to the prioritized OAR dose. However, there is some trade-off and optimizer variability also contributing to dose avoidance. The ability of the BBO TPS to optimize throughout the segmentation process (the DBO TPS is unable to achieve this) may also contribute to OAR avoidance at low dose levels. This enables intuitive back-up jaw/MLC interactions, via reshaping/reweighting of segments to reduce MLC dose leakage. This may reduce planned low dose transmission to OARs and targets, and contribute to the lower integral dose of the BBO plans.
Finally, constrained optimization of the BBO TPS (prioritization of OAR, as opposed to unconstrained optimization in DBO where targets and OAR compete for dose) results in improved OAR avoidance at the expense of potentially larger dose hot spots in the targets. The BBO optimization prioritizes OAR dose above hot spots in target volumes. This is potentially a significant dose trade-off, and requires careful clinician consideration to assess that hot spots and dose conformity within target volumes are clinically acceptable and justify further OAR avoidance. The study was unable to objectively quantify all aspects of target dose conformity across all dose levels in competing plans. This has the potential for bias in plan assessment with this inability for objective quantification. An increase in deliverable segments in the BBO planned cohort may also have some bearing on improved treatment plan quality.
Traditional biological-based planning relies on a biological assessment of plan quality-namely in the form of tumor control probability (TCP) and normal tissue complication probability (NTCP). While the utilized BBO TPS utilizes EUD-based objective functions for plan optimization, it fails to provide a biological alternative for plan assessment. It relies on traditional dose-volume based plan analysis, and is unable to quantify the potential biological response to the Table VI ).
With frequent 3D verification imaging, there is an increasing awareness of response related deformation in head and neck radiotherapy, revealing both parotid gland volume reduction and subsequent medial migration of the parotid glands.
As a consequence, discrepancies between estimated delivered dose and planned dose can occur. Several studies have shown significant variation to planned dose as a result of parotid shrinkage (29, 30) . Recent findings have reported the benefits of adaptive replanning to counteract intra-treatment parotid deformation (31, 32). Target delineation optimization and margin reduction were addressed as an effective avenue for target dose maintenance, while ensuring parotid gland dose avoidance was maintained to an acceptable level. When adaptive radiotherapy is combined with optimal planned dosimetry there presents an opportunity to maintain or further improve parotid gland avoidance.
Reduction in the inadvertent dose delivery to midline pharyngeal structures outside of the target volumes is a potentially beneficial finding of this study. A significant reduction to larynx V50 Gy has the potential for not only enhanced laryngeal functional preservation, but also subsequent preservation of the swallowing structures in its immediate vicinity. Dose reduction to midline structures adjacent to target volumes may reduce both acute and late consequences of inadvertent pharyngeal axis irradiation. A number of reports have highlighted that midline avoidance can have a significant influence in the reduction of long term treatment related dysphagia (7, 8, (33) (34) (35) . In an analysis of sixty six patients, Caglar et al. observed that laryngeal V50 Gy directly correlated with aspiration and stricture complications (11). When V50 Gy was less than 21%, aspiration and stricture complications were not seen. Publications from the Ghent group provide a possible reason for our dose increase from DBO SP to DBO MC (37, 38). They hypothesized that the presence of air within a given volume provides a relative reduction in particle interaction compared to surrounding tissues. Monte Carlo dose calculation engines would therefore create extra statistical noise in these air cavities-due to their ability to generate increased physical interactions-subsequently increasing dose (38). Tissue heterogeneities in the head and neck provide such interfaces, providing a basis for increased interactions in our plans. This is of particular relevance in larynx and targets, where soft tissue/air interfaces are apparent. This applies to a lesser extent to the remaining OARs.
Integral or healthy tissue dose has been a subject of review in IMRT planning and delivery (39, 40) . ICRU 62 stipulates that in order to optimize conformity indices, there needs to be a dose trade off to cater for the improved target/OAR conformality associated with three-dimensional and IMRT planning i.e. increased integral dose to unspecified healthy tissue (41). This theory is also pursued by Purdy and colleagues (39) . Whilst our study demonstrated equality in target coverage, and improvement in conformality and OAR avoidance, BBO was also able to deliver a superior result in healthy tissue avoidance at multiple dose levels (V20%, V15%, V10%, V5%)-delivering a lower integral dose to the patient. 
Conclusion
This planning study was undertaken to compare OAR avoidance in DBO and BBO in head and neck treatment planning. However, it was also performed to assess the clinical validity of a treatment planning system prior to clinical implementation. There was comparable target dose coverage, with dose to the OARs significantly reduced with the BBO planning alternative. The avoidance of dose limiting structures, such as larynx and parotids, has the potential to reduce acute and late side effects that may translate into improved quality of life outcomes for the head and neck patients receiving radical radiotherapy with or without concurrent chemotherapy. While not capable of providing the magnitude of biological response, EUD-based objectives used in the BBO TPS deliver dosevolume based improvements. With ongoing improvements to plan development and efficiency, it provides a platform for improved head and neck treatment planning. Prospective collection of patient outcomes in the clinical setting, using BBO treatment planning, will be undertaken and collated to determine the potential clinical benefit in routine practice.
Conflict of Interest
We certify that regarding this paper, no actual or potential conflicts of interests exist: the work is original, has not been accepted for publication nor is concurrently under consideration elsewhere, and will not be published elsewhere without the permission of the Editor and that all the authors have contributed directly to the planning, execution or analysis of the work reported or to the writing of the paper.
